- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Bilateral Pneumothoraces Secondary to Lenvatinib (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_6575; The pneumothorax may resolve with drainage and discontinuation of the TKI. While rare, it is important to recognize tumor necrosis secondary to multi-site targeting TKI can be a cause of recurrent and persistent pneumothoraces.
- |||||||||| lenvatinib / Generic mfg.
Clinical, Journal: Second-line lenvatinib in patients with recurrent endometrial cancer. (Pubmed Central) - Jul 3, 2020 While rare, it is important to recognize tumor necrosis secondary to multi-site targeting TKI can be a cause of recurrent and persistent pneumothoraces. Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov) - Jul 1, 2020 P2, N=600, Active, not recruiting, Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies. N=180 --> 600 | Trial completion date: Apr 2022 --> Feb 2024 | Trial primary completion date: Apr 2022 --> Feb 2024
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] COOPERATION BETWEEN DISTINCT CANCER DRIVER GENES UNDERLIES INTER-TUMOR HETEROGENEITY IN HEPATOCELLULAR CARCINOMA () - Jun 29, 2020 - Abstract #ILCA2020ILCA_30; Introduction: Several therapies are now approved for the treatment of advanced hepatocellular carcinoma patients, including the multikinase inhibitors sorafenib, regorafenib, lenvatinib, and cabozantinib, the VEGFR2 antagonist ramucirumab, and the immunotherapies pembrolizumab and nivolumab, the latter alone or in combination with ipilimumab... Altogether, this novel collection of murine HCC models and corresponding cell lines establishes the role of driver genes in diverse contexts and enables mechanistic and translational studies.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Emerging agents and regimens for hepatocellular carcinoma. (Pubmed Central) - Jun 28, 2020 The combination of an anti-PD-1 antibody and an anti-angiogenesis agent has shown more potent anti-tumor effects in early phase clinical trials and is now the hotspot in clinical studies. Furthermore, these agents are investigated in combination treatment with surgery or other loco-regional therapies in patients with early or intermediate-stage HCC.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. (Pubmed Central) - Jun 27, 2020 Pharmacist interventions in collaboration with medical oncologists improved lenvatinib therapy. Interventions for outpatients were conducted not only in outpatient clinics but also by telephone follow-up, clarifying the importance of continuous management for patients at risk of adverse reactions and misuse of oral medicine.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) (clinicaltrials.gov) - Jun 22, 2020 P=N/A, N=20, Not yet recruiting,
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Dulect2020-2: Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jun 22, 2020 P=N/A, N=20, Not yet recruiting,
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers (clinicaltrials.gov) - Jun 22, 2020 P2, N=44, Not yet recruiting, Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> Dec 2023 Initiation date: Feb 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2022
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Tafinlar (dabrafenib) / Novartis
[VIRTUAL] Complex Thyroid Cancer with Several Recurrences and Metastases () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2116; This patient demonstrated excellent response to I-131 therapy with lenvatinib pretreatment.A number of formal studies of various TKIs for thyroid cancer re-differentiation are currently underway. (cite Brown SR, Hall A, et al BMC cancer 2019; and also cite the CIII trial with cabozatanib)Conclusion This case represents the emerging paradigm for the ability of TKI therapy to redifferentiate advanced thyroid cancer and allow for re-treatment with I-131 targeted therapy.
- |||||||||| Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. (Pubmed Central) - Jun 19, 2020 Following a decade of negative Phase III trials since the approval of sorafenib, more recently several drugs have proven efficacy both in first line versus sorafenib (lenvatinib) or in second line versus placebo (regorafenib, cabozantinib, ramucirumab)...For the first time in the history of systemic treatments for HCC, a predictive factor of efficacy was identified. In this review, we also discuss the potential clinical development of systemic treatments in HCC, focusing on combination therapies with immunotherapy (following the recent results of the combination of atezolizumab and bevacizumab in the IMbrave 150 clinical trial) and treatment sequences as a way to maximize survival benefit.
|